Prostate Tissue BioBank for Prostate Cancer and Genetic Predisposition
This study, called the Prostate Tissue BioBank, is collecting prostate tissue samples and DNA from men with prostate cancer. Researchers are particularly interested in men who have inherited gene changes (mutations) in genes like ATM, BRCA1, BRCA2, and TP53, which are known to increase prostate cancer risk. They will also collect samples from men without these mutations for comparison. The goal is to create a collection of these samples to better understand how these genetic changes affect prostate cancer. This information will help researchers learn more about prostate cancer and potentially develop better ways to detect and treat it. The study plans to enroll 200 participants.
- Study design
- This is an observational study, meaning participants will be observed without receiving a specific intervention. It aims to enroll 200 participants.
- What's involved
- Participants will provide prostate tissue samples from biopsies or prostatectomies, and matched germline DNA.
- Compensation
- Not stated in the trial record.
- Follow-up
- Clinical and pathological data for patients with prostate tissue samples will be measured at 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Prostate Tissue BioBank
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kara N Maxwell, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Clinical and pathological data for patients with prostate tissue samples5 years
Data will be collected on consented patients who undergo prostate biopsy, prostatectomy or metastatic biopsy.